Pure Global
NCT05804383

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease
Allyx Therapeutics·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
BMS-984923
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Allyx Therapeutics
Location
New Haven,West Bend, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 28, 2023
End date
Jul 15, 2024
Enrollment
50 participants
Primary outcome

Stage 1 and Stage 2 Incidence of treatment-emergent adverse events (TEAEs),Stage 1 and Stage 2 Incidence of clinically significant lab abnormalities,Stage 1 Incidence of clinically significant changes in safety assessments,Stage 2 Incidence of clinically significant changes in safety assessments

Summary

A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in
 Healthy Older Adults and Patients with Alzheimer's Disease

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05804383
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05804383 through Pure Global AI's free database. This Phase 1 trial is sponsored by Allyx Therapeutics and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.